Consensus CSPC Pharmaceutical Group Limited

Stocks

1093

HK1093012172

Pharmaceuticals

Delayed Hong Kong S.E. 04:17:24 20/10/2026 BST			5-day change	1st Jan Change
8.925 ^HKD	+2.59%		-1.54%	+5.87%

10-19	Pharma sector doubles down on AI to slash costs, timelines	RE
10-19	Major drugmakers turn to China for licensing deals	RE

Evolution of the Average Target: CSPC Pharmaceutical Group Limited

Evolution of the Target Price: CSPC Pharmaceutical Group Limited

Changes in Analyst Recommendations: CSPC Pharmaceutical Group Limited

b94fffc978e37732.LwjqLYwAPGP2VtPqSuqka5xCfJEK5REDEnwmRKLzS7U.G3y5ZMJUfjzFEYXfcr_vCsNwCeVQp3BLcy1kAPOjetR8fb1BznpwO8I9ng~e969f9ad866d9ff0f2f9e8bc1b169ac1

Analysts' recommendations: CSPC Pharmaceutical Group Limited

08-24	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.93 From HK$10.31, Keeps at Buy	MT
08-21	UOB Kay Hian Upgrades CSPC Pharmaceutical Group to Buy from Sell; Price Target is HK$11.50	MT
07-27	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.31 From HK$12.04, Keeps at Buy	MT
05-28	UOB Kay Hian Downgrades CSPC Pharmaceutical Group to Sell from Hold; Price Target is HK$6	MT
03-26	Jefferies Adjusts CSPC Pharmaceutical Group's Price Target to HK$7.20 From HK$5.90, Keeps at Underperform	MT
02-16	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy	MT
11-21	UOB Kay Hian Downgrades CSPC Pharmaceutical Group to Hold from Buy; Price Target is HK$8.50	MT
11-21	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$9.11 from HK$10.09, Keeps at Buy	MT
20/10/25	CSPC Pharmaceutical says JSKN003 granted breakthrough therapy designation in China	RE
13/10/25	CSPC Pharmaceutical announces NMPA acceptance of new drug application for Efmedaglutide Alfa Injection	RE
09/10/25	CSPC Pharmaceutical's Hypertriglyceridemia Drug Secures FDA Nod for US Trial	MT
25/08/25	Jefferies Adjusts CSPC Pharmaceutical Group's Price Target to HK$5.90 From HK$5, Keeps at Underperform	MT
17/07/25	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.09 From HK$10.22, Keeps at Buy	MT
16/07/25	Macquarie Upgrades CSPC Pharmaceutical Group to Outperform from Neutral; Price Target is HK$10.30	MT
16/06/25	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.22 From HK$8.02, Keeps at Buy	MT
29/05/25	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$8.02 From HK$6.55, Keeps at Buy	MT
31/03/25	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$6.55 From HK$6.48, Keeps at Buy	MT
26/02/25	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$6.48 From HK$7.02, Keeps at Buy	MT
18/11/24	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$7.02 From HK$8.46, Keeps at Buy	MT
22/10/24	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$8.46 From HK$9.29, Keeps at Buy	MT
23/08/24	Zhongtai International Downgrades CSPC Pharmaceutical to Neutral From Buy; Price Target is HK$6.10	MT
22/08/24	Nomura Adjusts CSPC Pharmaceutical's Price Target to HK$9.29 From HK$9.83, Keeps at Buy	MT
22/08/24	Daiwa Securities Downgrades CSPC Pharmaceutical to Neutral From Outperform; Price Target is HK$6	MT
22/08/24	UOB Kay Hian Downgrades CSPC Pharmaceutical to Sell From Buy; Price Target is HK$5	MT
22/08/24	Bank of China International Downgrades CSPC Pharmaceutical to Hold From Buy; Price Target is HK$6.50	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CSPC PHARMACEUTICAL GROUP LIMITED					+42.68%
	ELI LILLY AND COMPANY					+5.65%
	JOHNSON & JOHNSON					+9.33%
	ABBVIE INC.					-0.99%
	ROCHE HOLDING AG					-0.52%
	MERCK & CO., INC.					+8.56%
	NOVARTIS AG					-0.8%
	ASTRAZENECA PLC					+26.78%
	AMGEN INC.					-8.67%
	GILEAD SCIENCES, INC.					+2.34%
	Average					+8.44%
	Weighted average by Cap.					+5.09%